Thrive Capital Management, LLC Neurocrine Biosciences Inc Transaction History
Thrive Capital Management, LLC
- $218 Million
- Q4 2024
A detailed history of Thrive Capital Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Thrive Capital Management, LLC holds 11,176 shares of NBIX stock, worth $1.26 Million. This represents 0.7% of its overall portfolio holdings.
Number of Shares
11,176
Previous 4,055
175.61%
Holding current value
$1.26 Million
Previous $466,000
227.25%
% of portfolio
0.7%
Previous 0.22%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.6 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.14 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$553 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$341 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$287 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...